Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Rapporto sulle azioni

Cap. di mercato: US$472.1m

Y-mAbs Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Y-mAbs Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 19.8%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 19.1%. I ricavi sono stati in crescita a un tasso medio annuo di 46.7%.

Informazioni chiave

19.8%

Tasso di crescita degli utili

23.9%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavi46.7%
Rendimento del capitale proprio-25.8%
Margine netto-28.2%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Ripartizione dei ricavi e delle spese

Come Y-mAbs Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGS:YMAB Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 2485-245049
30 Jun 2487-255154
31 Mar 2484-224553
31 Dec 2385-214550
30 Sep 2393-194456
30 Jun 2385-394862
31 Mar 2375-745076
31 Dec 2265-965289
30 Sep 2243-1345798
30 Jun 2240-1355799
31 Mar 2240-1175892
31 Dec 2135-555791
30 Sep 2146-385686
30 Jun 2137-425484
31 Mar 2126-605095
31 Dec 2021-1194693
30 Sep 200-1233886
30 Jun 200-1143185
31 Mar 200-912469
31 Dec 190-812063
30 Sep 190-721657
30 Jun 190-591447
31 Mar 190-521240
31 Dec 180-43934
30 Sep 180-38930
30 Jun 180-31724
31 Mar 180-24518
31 Dec 170-19514

Guadagni di qualità: YMAB al momento non è redditizia.

Margine di profitto in crescita: YMAB al momento non è redditizia.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: YMAB non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 19.8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di YMAB nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: YMAB non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).


Rendimento del capitale proprio

ROE elevato: YMAB ha un Return on Equity negativo ( -25.82% ), in quanto al momento non è redditizio.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate